Page last updated: 2024-11-08

methylselenic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methylseleninic acid : An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID161597
CHEMBL ID399906
CHEBI ID77012
SCHEMBL ID772883
MeSH IDM0052378

Synonyms (21)

Synonym
methylselenic acid
methaneseleninic acid
methylseleninic acid
methaneseleninic acid, 95%
nsc-244776
nsc-243621
28274-57-9
methylseleninate
CHEMBL399906
chebi:77012 ,
C18902
9900c6v162 ,
unii-9900c6v162
methaneseleninic acid(6ci,8ci,9ci)
AKOS025296197
J1.001.675D ,
SCHEMBL772883
methylhydroxy selenoxide
DTXSID9040550
methyl seleninic acid
Q6823570

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Methylseleninic acid, l-selenocystine, selenodiglutathione or selenite induced cell death in micromolar concentrations, whereas selenomethionine or ebselen was not toxic within the concentration range tested."( Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture.
Birringer, M; Hoefig, CS; Köhrle, J; Renko, K; Schomburg, L, 2011
)
0.37
" Previous studies have demonstrated that patulin can cause diverse toxic effects in animals including hepatotoxicity and nephrotoxicity."( Methylseleninic Acid Prevents Patulin-Induced Hepatotoxicity and Nephrotoxicity via the Inhibition of Oxidative Stress and Inactivation of p53 and MAPKs.
Fan, L; Hu, H; Lu, X; Yin, S; Zhang, E, 2017
)
0.46
" This review contains generalized information on the dose- and time-dependent regulation of the toxic effect of methylseleninic acid on the proliferative properties of a number of cancer cell lines."( THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS.
Turovsky, EA; Varlamova, EG, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The bioavailability and distribution of the two selenium sources in major organs/tissues were compared under exactly identical conditions."( Preferential organ distribution of methylselenol source Se-methylselenocysteine relative to methylseleninic acid.
Ohta, Y; Suzuki, KT; Suzuki, N; Tsuji, Y, 2008
)
0.35
" These results suggest that SeMet may improve glucose tolerance in a NA/STZ-induced mild diabetic mouse model by increasing bioavailability in the pancreas."( Effects of administering sodium selenite, methylseleninic acid, and seleno-L-methionine on glucose tolerance in a streptozotocin/nicotinamide-induced diabetic mouse model.
Arakawa, T; Nakamuro, K; Ogino, H; Okuno, T; Sakazaki, F; Shimizu, R; Ueno, H, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" We tested the hypothesis that oral dosing methylseleninic acid (MSeA), a methylselenol precursor, inhibits the growth of colon cancer xenografts in C57BL/6 mice fed a Se adequate diet."( The Inhibitory Efficacy of Methylseleninic Acid Against Colon Cancer Xenografts in C57BL/6 Mice.
Wu, M; Zeng, H, 2015
)
0.42
" However, the dose-response relationship in normal versus malignant human cells is unclear."( The Interaction of Selenium with Chemotherapy and Radiation on Normal and Malignant Human Mononuclear Blood Cells.
Cursons, RT; Jacobson, GM; Jameson, MB; Lobb, RJ, 2018
)
0.48
" Aggressive dosing of these therapies is significantly hampered by side effects due to normal tissue toxicity."( Methylseleninic Acid Induces Lipid Peroxidation and Radiation Sensitivity in Head and Neck Cancer Cells.
Buettner, GR; Goswami, PC; Kalen, AL; Lafin, JT; Sarsour, EH; Wagner, BA, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
EC 3.5.1.98 (histone deacetylase) inhibitorAn EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
organoselenium compoundAn organoselenium compound is a compound containing at least one carbon-selenium bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Selenoamino acid metabolism2450
Metabolism of ingested MeSeO2H into MeSeH18
Formation of selenosugars for excretion011

Bioassays (16)

Assay IDTitleYearJournalArticle
AID310681Cytotoxicity against human PC3 cells at 2 to 10 uM by MTT assay2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Novel potent organoselenium compounds as cytotoxic agents in prostate cancer cells.
AID1410296Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1331618Selectivity index, ratio of GI50 for human 184B5 cells to GI50 for human MCF7 cells2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1410297Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1410294Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1331616Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1410293Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1410298Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1331617Cytotoxicity against human 184B5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1331615Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1410295Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1191162Cytotoxicity against human PC3 cells assessed as inhibition of cell growth2015European journal of medicinal chemistry, Jan-27, Volume: 90Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue.
AID1410301Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1410300Selectivity index, ratio of GI50 for human 184B5 cells to GI50 for human MCF7 cells2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1410299Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
AID1410302Selectivity index, ratio of GI50 for human BEAS2B cells to GI50 for human HTB-54 cells2018ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4
Combined Acylselenourea-Diselenide Structures: New Potent and Selective Antitumoral Agents as Autophagy Activators.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's59 (42.14)29.6817
2010's72 (51.43)24.3611
2020's9 (6.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.26 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.69%)5.53%
Reviews5 (3.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other138 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]